BioWorld

March 28, 2006

Encysive Shares Tumble On FDA Thelin Approvable Letter

Encysive Pharmaceuticals Inc. lost almost half its stock value Monday on news that the FDA may require additional clinical trial work for the pulmonary arterial hypertension drug Thelin. (BioWorld Today) Read More

Corgentech’s Phase II Study With VR1 Agonist Negative

Keryx Pads Balance Sheet With $83M Direct Stock Sale

Systemic RNAi Data Leads To Alnylam Partnership With INEX

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...